PECAM1 and rosacea: These results indicate that topical CBG inhibits angiogenic and mechanosensitive pathways by concurrently reducing mRNA and protein levels of CD31, VEGF, YAP, and TAZ, thereby contributing to the reduction of vascular activation in rosacea-like inflammation.